Submissions

These comments address the four parabens that are on the prioritization list. As these ingredients serve an important preservative function and have been extensively reviewed and approved by expert bodies, they should be considered low priority for DARTIC review.

These comments address titanium dioxide nanoparticles, which serve an important function in numerous consumer products, including sunscreens.

As FDA is recognized as an authoritative body by Proposition 65, we believe that OEHHA should await the outcome of FDA's review rather than bringing BP-3 to the DARTIC for review.

Enclosed are comments regarding the OEHHA draft report entitled " Health Effects Assessment: Potential Neurobehavioral Effects of Synthetic Food Dyes in Children."

On behalf of the Consumer Healthcare Products Association, enclosed herein are comments on the 2019 revised draft guidance document as well as FDA’s decision to revoke CPG 400.400.

While the “essential workforce” list is solely advisory in nature, it provides much-needed guidance to state and local governments as they proceed with their own “stay at home” orders across the country. It is important to make this list as precise as possible with few vagueries that can be left to interpretation.

It is imperative that the federal, state, and local governments come together with uniform definitions of “critical infrastructure”, making clear what manufacturers must continue to operate, and take seriously the need to transport those products and keep operations running.

We strongly agree that healthcare product manufacturers have a central role to play in the fight against this pandemic. Provided employers comply with CDC guidelines to protect workers, healthcare product manufacturers have the special responsibility to maintain their current work schedules.

Enclosed are comments on “Transdermal and Topical Delivery Systems - Product Development and Quality Considerations”. CHPA and our member companies marketing external analgesic ingredients have an interest, experience, and expertise in this area and appreciate this opportunity to comment.

The DEA invited comments on the proposed rule to revise existing regulations that manage quotas for controlled substances and List I chemicals held by DEA-registered manufacturers. We have comments on three areas within the proposed rule.